Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)

202326 citationsJournal Articlehybrid Open Access

Authors

Orismilast demonstrated greater efficacy vs placebo and a safety profile in line with PDE4 inhibition.

Good health and well-being

Published in: Journal of the American Academy of Dermatology

Volume 90, Issue 3, pp. 494-503

Field-Weighted Citation Impact: 4.33